ForSight Labs

About ForSight Labs

ForSight Labs, LLC operates as a specialized incubator in the ophthalmology sector, focused on identifying and developing technologies to address vision impairment. Established in 2005, the firm was the result of a collaboration between the medical device incubator The Foundry and Dr. Eugene de Juan, Jr., a distinguished ophthalmologist, retinal surgeon, and serial entrepreneur with a history of co-founding successful ventures like Second Sight and InnoRx. Dr. de Juan's extensive background in developing ophthalmic innovations, holding dozens of patents, and his clinical work at institutions like Johns Hopkins University and UCSF, provided the foundational expertise for the lab's mission. Joining him was K. Angela Macfarlane, who serves as CEO. Her journey into medtech was driven by an interest in the intellectual property strategies of early-stage startups, leading her through roles at VidaMed and as technology counsel for The Foundry before heading ForSight Labs.

The company's business model is centered on creating, funding, and spinning out new companies, known as the "VISION" series, each targeting a specific high-impact need within eye care. ForSight Labs provides the initial concept, development resources, and collaborates with entrepreneurs and investors to bring these technologies to commercialization. This incubator model has proven successful, with the lab launching six companies that have collectively raised over $200 million. These spinouts include Transcend Medical (acquired by Alcon), ForSight Newco II (acquired by QLT), ForSight VISION4 (acquired by Roche), and ForSight VISION5 (acquired by Allergan), demonstrating a consistent track record of creating valuable assets for major players in the pharmaceutical and medical device industries. For instance, ForSight VISION4 developed a proprietary Port Delivery System (PDS) for long-acting drug delivery to the eye, which led to its acquisition by Roche. Similarly, other spinouts have focused on areas like glaucoma treatment and non-invasive drug delivery systems that replace traditional eye drops.

ForSight Labs operates in the biotechnology and medical device markets, backed by prominent venture capital firms such as Morgenthaler Ventures, Versant Ventures, and Split Rock Partners. Its revenue is generated through the successful exit of its portfolio companies via acquisitions or licensing agreements with larger corporations. The Menlo Park-based incubator serves as a hub where scientific, clinical, and entrepreneurial expertise converges to solve significant challenges in ophthalmology, ultimately aiming to improve the quality of life for patients with visual impairments.